Literature DB >> 18264127

Enhanced antithrombotic effects of unfractionated heparin in rats after repeated oral doses and its relationship to endothelial heparin concentration.

L M Hiebert1, T Ping, S M Wice.   

Abstract

BACKGROUND AND
PURPOSE: An oral, single dose of 7.5 mg kg(-1) of unfractionated heparin (UFH) reduces thrombosis by 50% in a rat model of venous thrombosis. As long-term use is required clinically, our objectives were to study the antithrombotic effects following repeated oral UFH administration. EXPERIMENTAL APPROACH: Bovine lung UFH was administered by oral gavage to rats in 3 doses of 7.5 mg kg(-1) each 12, 24, 48, and 72 h apart; and in 3 or 15 doses of 1 mg kg(-1) every 48 h. The last dose was given immediately after thrombus initiation where 10% formalin in methanol was applied to the jugular vein. The vessel was examined for thrombosis 4 h later. Amounts of heparin in tissue and endothelium, and plasma anticoagulant activity were measured. KEY
RESULTS: When 3 x 7.5 mg kg(-1) heparin was given, thrombotic incidence was most reduced at 48 h dose-intervals and was significantly less than single dose treatment. There was a negative correlation between endothelial heparin content and thrombotic incidence, but not anticoagulant activity. When 3 doses of 1 mg kg(-1) every 48 h were given, thrombotic incidence was similar to single dose treatment. When 15 doses were given, total thrombotic incidence was less than for 3 doses and was similar to that after s.c. administration. CONCLUSIONS AND IMPLICATIONS: Antithrombotic activity increased with repeated doses of oral UFH, with antithrombotic effects similar to s.c. administration. Antithrombotic activity was related to heparin on endothelium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18264127      PMCID: PMC2275434          DOI: 10.1038/bjp.2008.14

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients.

Authors:  Francesco Dentali; James D Douketis; Monica Gianni; Wendy Lim; Mark A Crowther
Journal:  Ann Intern Med       Date:  2007-02-20       Impact factor: 25.391

Review 2.  The role of heparin and allied compounds in the treatment of sepsis.

Authors:  Alexander D Cornet; Ellen G M Smit; Albertus Beishuizen; A B Johan Groeneveld
Journal:  Thromb Haemost       Date:  2007-09       Impact factor: 5.249

3.  Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

Authors:  M Dryjski; D E Schneider; P Mojaverian; B S Kuo; T D Bjornsson
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

4.  Oral heparin in the treatment of rheumatoid arthritis.

Authors:  J Imiela; J Nosarzewski; A Górski
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1995       Impact factor: 4.291

5.  Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.

Authors:  L Bara; A Planes; M M Samama
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

Review 6.  Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis.

Authors:  S R Money; J W York
Journal:  Cardiovasc Surg       Date:  2001-06

7.  Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin.

Authors:  Devang N Prajapati; Julianne R Newcomer; Jeanne Emmons; Majed Abu-Hajir; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2002-05       Impact factor: 5.325

8.  Orally administered heparins prevent arterial thrombosis in a rat model.

Authors:  Cory Pinel; Sandra M Wice; Linda M Hiebert
Journal:  Thromb Haemost       Date:  2004-05       Impact factor: 5.249

Review 9.  From Trousseau to targeted therapy: new insights and innovations in thrombosis and cancer.

Authors:  M N Levine; A Y Lee; A K Kakkar
Journal:  J Thromb Haemost       Date:  2003-07       Impact factor: 5.824

10.  Antithrombotic activity of oral unfractionated heparin.

Authors:  L M Hiebert; S M Wice; L B Jaques
Journal:  J Cardiovasc Pharmacol       Date:  1996-07       Impact factor: 3.105

View more
  5 in total

1.  Endothelium in pharmacology: 30 years on.

Authors:  J C McGrath
Journal:  Br J Pharmacol       Date:  2009-06       Impact factor: 8.739

2.  Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs.

Authors:  Malathi Erickson; Linda M Hiebert; Anthony P Carr; Jocelyn D Stickney
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

3.  Effects of wasp venom on venous thrombosis in rats.

Authors:  Fan-Mao Jin; Mei Wang; Xiu-Mei Wu; Huai Xiao; De-Xiao Wang; Guang-Ming Wang; Cheng-Gui Zhang; Hai-Rong Zhao
Journal:  Iran J Basic Med Sci       Date:  2022-07       Impact factor: 2.532

4.  Heparin and related drugs: beyond anticoagulant activity.

Authors:  Clive Page
Journal:  ISRN Pharmacol       Date:  2013-07-30

5.  Antithrombotic Activity of Heparinoid G2 and Its Derivatives from the Clam Coelomactra antiquata.

Authors:  Guanlan Chen; Rui Zeng; Xin Wang; Hongying Cai; Jiajia Chen; Yingxiong Zhong; Saiyi Zhong; Xuejing Jia
Journal:  Mar Drugs       Date:  2022-01-05       Impact factor: 5.118

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.